Abnormal Aminopyrine Metabolism in Patients With Hepatic Neoplasm: Detection by Breath Test

Gershon W. Hepner, Stephen R. Uhlin, Allan Lipton, Harold A. Harvey, G. Victor Rohrer

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Aminopyrine metabolism was assessed by the aminopyrine breath test (ABT) in 153 patients with malignant disease, of whom 75 had hepatic neoplasm and 78 had none. Radioactive carbon dioxide (14CO2) exhalation was measured two hours after oral administration of a trace dose of carbon-14 labeled aminopyrine. The ABT was correct in 62 of 75 (83%) patients with hepatic neoplasm and in 73 of 78 (94%) patients without. It was correct in 16 of 22 (73%) patients who had hepatic neoplasm without abnormal serum biochemistry. Aminopyrine metabolic clearance rate (AMCR) was 32.4 ml/min in patients with hepatic neoplasm and 103.4+18.8 ml/min in the patients without. There was a highly significant correlation between ABT and AMCR (r=.76, P <.01). We conclude that aminopyrine metabolism is depressed in most patients with hepatic neoplasm and that the ABT affords a useful method for detecting malignant tumors of the liver.

Original languageEnglish (US)
Pages (from-to)1587-1590
Number of pages4
JournalJAMA: The Journal of the American Medical Association
Volume236
Issue number14
DOIs
StatePublished - Oct 4 1976

Fingerprint

Aminopyrine
Breath Tests
Liver Neoplasms
Metabolic Clearance Rate
Exhalation
Carbon Dioxide
Biochemistry
Oral Administration
Carbon

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{ab01f080628b43929c8fe42aedc6a015,
title = "Abnormal Aminopyrine Metabolism in Patients With Hepatic Neoplasm: Detection by Breath Test",
abstract = "Aminopyrine metabolism was assessed by the aminopyrine breath test (ABT) in 153 patients with malignant disease, of whom 75 had hepatic neoplasm and 78 had none. Radioactive carbon dioxide (14CO2) exhalation was measured two hours after oral administration of a trace dose of carbon-14 labeled aminopyrine. The ABT was correct in 62 of 75 (83{\%}) patients with hepatic neoplasm and in 73 of 78 (94{\%}) patients without. It was correct in 16 of 22 (73{\%}) patients who had hepatic neoplasm without abnormal serum biochemistry. Aminopyrine metabolic clearance rate (AMCR) was 32.4 ml/min in patients with hepatic neoplasm and 103.4+18.8 ml/min in the patients without. There was a highly significant correlation between ABT and AMCR (r=.76, P <.01). We conclude that aminopyrine metabolism is depressed in most patients with hepatic neoplasm and that the ABT affords a useful method for detecting malignant tumors of the liver.",
author = "Hepner, {Gershon W.} and Uhlin, {Stephen R.} and Allan Lipton and Harvey, {Harold A.} and Rohrer, {G. Victor}",
year = "1976",
month = "10",
day = "4",
doi = "10.1001/jama.1976.03270150021022",
language = "English (US)",
volume = "236",
pages = "1587--1590",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "14",

}

Abnormal Aminopyrine Metabolism in Patients With Hepatic Neoplasm : Detection by Breath Test. / Hepner, Gershon W.; Uhlin, Stephen R.; Lipton, Allan; Harvey, Harold A.; Rohrer, G. Victor.

In: JAMA: The Journal of the American Medical Association, Vol. 236, No. 14, 04.10.1976, p. 1587-1590.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Abnormal Aminopyrine Metabolism in Patients With Hepatic Neoplasm

T2 - Detection by Breath Test

AU - Hepner, Gershon W.

AU - Uhlin, Stephen R.

AU - Lipton, Allan

AU - Harvey, Harold A.

AU - Rohrer, G. Victor

PY - 1976/10/4

Y1 - 1976/10/4

N2 - Aminopyrine metabolism was assessed by the aminopyrine breath test (ABT) in 153 patients with malignant disease, of whom 75 had hepatic neoplasm and 78 had none. Radioactive carbon dioxide (14CO2) exhalation was measured two hours after oral administration of a trace dose of carbon-14 labeled aminopyrine. The ABT was correct in 62 of 75 (83%) patients with hepatic neoplasm and in 73 of 78 (94%) patients without. It was correct in 16 of 22 (73%) patients who had hepatic neoplasm without abnormal serum biochemistry. Aminopyrine metabolic clearance rate (AMCR) was 32.4 ml/min in patients with hepatic neoplasm and 103.4+18.8 ml/min in the patients without. There was a highly significant correlation between ABT and AMCR (r=.76, P <.01). We conclude that aminopyrine metabolism is depressed in most patients with hepatic neoplasm and that the ABT affords a useful method for detecting malignant tumors of the liver.

AB - Aminopyrine metabolism was assessed by the aminopyrine breath test (ABT) in 153 patients with malignant disease, of whom 75 had hepatic neoplasm and 78 had none. Radioactive carbon dioxide (14CO2) exhalation was measured two hours after oral administration of a trace dose of carbon-14 labeled aminopyrine. The ABT was correct in 62 of 75 (83%) patients with hepatic neoplasm and in 73 of 78 (94%) patients without. It was correct in 16 of 22 (73%) patients who had hepatic neoplasm without abnormal serum biochemistry. Aminopyrine metabolic clearance rate (AMCR) was 32.4 ml/min in patients with hepatic neoplasm and 103.4+18.8 ml/min in the patients without. There was a highly significant correlation between ABT and AMCR (r=.76, P <.01). We conclude that aminopyrine metabolism is depressed in most patients with hepatic neoplasm and that the ABT affords a useful method for detecting malignant tumors of the liver.

UR - http://www.scopus.com/inward/record.url?scp=0017298261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017298261&partnerID=8YFLogxK

U2 - 10.1001/jama.1976.03270150021022

DO - 10.1001/jama.1976.03270150021022

M3 - Article

C2 - 989131

AN - SCOPUS:0017298261

VL - 236

SP - 1587

EP - 1590

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 14

ER -